Dactolisib

Description: Dactolisib (BEZ235) is an orally bioavailable inhibitor of PI3K and mTOR, with IC50 values of 4 nM for p110alpha, 5 nM for p110gamma, 7 nM for p110delta, 75 nM for p110beta, and 20.7 nM for mTOR. Target: ATM/ATR, Autophagy, PI3K, mTOR. Smiles: O=C1N(C=2C=3C(N=CC2N1C)=CC=C(C3)C4=CC5=C(N=C4)C=CC=C5)C6=CC=C(C(C#N)(C)C)C=C6. References: Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008 Jul,7(7):1851-63.